Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), doselimiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).
Introduction
Phosphatidylinositol-3-kinase (PI3K) regulates processes involved in the hallmark traits of cancer, such as cell growth, survival, metabolism, invasion, and metastases (1). Multiple isoforms of PI3K exist in mammalian cells and these isoforms are subdivided into three classes based on structural features and lipid substrate preferences (1). The class IA isoforms (p110a, b, and d) are responsible for the production of the second messenger phosphatidyl-inositol-3,4,5 triphosphate (PIP 3 ; refs. 2, 3) . PI3K activation initiates a signal transduction cascade, of which the major effectors are the kinases AKT and mTORC1 (4) . PTEN is a tumor-suppressor gene that functions as a phosphatase, and is the primary negative regulator of PI3K, through hydrolysis of PIP 3 (5) . Deregulation of the PI3K pathway has been frequently implicated in a wide range of malignancies, including glioma, prostate, breast, ovarian, and endometrial cancer (6) . Alteration of the pathway commonly occurs through mutation or amplification of PIK3CA that encodes the p110a catalytic subunit, loss of function of PTEN (through deletion, mutation, or reduced expression), alterations in the INPP4B and PHLPP phosphatases, mutations of the PI3K regulatory subunits encoded by PIK3R1 and PIK3R3, or through activation of upstream receptor tyrosine kinases or cross-talk with the RAS pathway (3, 6, 7) .
Pictilisib (GDC-0941; Genentech Inc.) is an oral, potent, selective pan-inhibitor of class I PI3K (IC 50 against purified recombinant human PI3K isoforms: p110a ¼ 3 nmol/L, p110b ¼ 33 nmol/L, p110d ¼ 3 nmol/L, and p110g ¼ 75 nmol/L) with 193-fold less activity against mTOR compared to p110a (8) . Antitumor activity was demonstrated in human tumor xenograft murine models; at an oral dose of 150 mg/kg, pictilisib achieved 98% and 80% growth inhibition in PI3K pathwayactivated U87MG glioblastoma and IGROV1 ovarian cancer xenografts, respectively (9) . At this dose level, pictilisib achieved plasma concentrations in tumor tissue >GI 50 -antiproliferative concentrations for >8 hours and demonstrated downstream PI3K pathway biomarker changes such as time-and dose-dependent inhibition of phosphorylation of AKT (Ser 473 ) and P70S6 kinase (Thr 421 /Ser 424 ; ref. 9) . These data led us to conduct a first-in-human phase I dose-escalation study of pictilisib in patients with advanced solid tumors to evaluate safety and tolerability, define dose-limiting toxicities (DLT) and the maximum-tolerated dose (MTD) of pictilisib administered orally. Secondary objectives included characterization of pharmacokinetics, assessment of pharmacodynamics including changes in tumor 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake [by positron emission tomography (PET) studies], tumor expression of phosphorylated (Ser 235 /Ser 236 ) S6 ribosomal protein (phospho-S6) in mandatory pre-and on-treatment biopsies and phosphorylated (Ser 473 ) AKT (phospho-AKT) in PRP, and preliminary evaluation of antitumor activity.
Patients and Methods
This single-center trial was conducted in accordance with the Declaration of Helsinki at The Royal Marsden NHS Foundation Trust (London, United Kingdom) after approval by local Institutional Review Boards. Informed consent from all patients was obtained.
Eligibility
Patients of ages !18 years with histologically confirmed solid tumors and no conventional treatment option were eligible. Other inclusion criteria included fasting serum glucose 120 mg/dL, HbA 1c upper limit of normality, prior chemotherapy or radiotherapy completed !4 weeks previously, toxicity from prior therapy resolved to grade 1, an Eastern Cooperative Oncology Group (ECOG) performance status 1, expected life expectancy !12 weeks, and adequate organ functions. Significant exclusion criteria included diabetes mellitus requiring medication, significant respiratory disease [requiring supplemental oxygen or predicted diffusion capacity of carbon monoxide (DL CO ) 50%], and use of anticoagulation or chronic corticosteroid.
Study design
This was an open-label, single-center, phase I study using a modified 3þ3 dose-escalation design. During dose escalation, the dose of pictilisib was doubled until drug-related toxicity of grade !2 was observed. Dose escalations from this point were limited to 50% of the previous dose (if grade 2) or 33% in the event of grade !3 toxicities.
Pictilisib was administered on day 1, followed by a 1-week washout to evaluate single-dose pharmcokinetics and pharmacodynamics. Dosing was once-daily for 21 or 28 days every 28 days (21/28 or 28/28 schedule, respectively). The recommended starting dose in humans of 15 mg once-daily was chosen on the basis of the no observed adverse effect level and MTD in 28-day rodent and dog species studies. The 21/28 starting schedule was chosen to implement a drug-free period to allow recovery from acute toxicities and limit cumulative toxicities to maximize the administered dose of pictilisib. A continuous dosing schedule (28/28) was implemented to further explore safety and pharmacodynamics of dose levels of 330 to 400 mg.
Definitions of DLT and MTD
DLTs were based on toxicities observed in the first cycle and assessed by the investigator as possibly related to pictilisib. A DLT was defined as grade 4 neutropenia for >5 days or accompanied by fever >38.5 C, grade 4 thrombocytopenia, or grade 3 nonhematologic toxicity of any duration with the exception of alopecia. Grade 3-4 nausea, vomiting, and diarrhea were only considered DLTs if they occurred despite optimal medical management. Grade !3 total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were considered DLTs except when preexisting grade 1 values and were <7.5x ULN due to known liver metastases. Decreases in DLco !20% were also considered DLTs. The MTD was defined as the highest dose at which 1 of 6 DLTs (<33%) patients experienced DLT at that dose level.
Safety and efficacy
Clinical and laboratory assessments were conducted at baseline and weekly thereafter. Safety assessments included medical
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history, physical examination, electrocardiogram, hematology, biochemistry (including fasting glucose and HbA 1C ,), and assessment of pulmonary toxicity with pulse oximetry, DL CO , and highresolution CT (HRCT) of the chest. Adverse events (AE) were graded using Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. Tumor assessments were performed at the end of cycles 1 and 2, and then every two cycles using RECIST guidelines (10) .
Pharmacokinetics
Plasma levels of pictilisib were determined from samples collected on day 1: pre-dose, and 0.5, 1, 2, 3, 4, 8, 24, 48, and 72 hours after dose; and on day 15: pre-dose, and 0.5, 1, 2, 3, 4, 8, and 24 hours after dose. Pharmacokinetic samples for pictilisib were analyzed using a validated HPLC/MS/MS method. Standard pharmacokinetic parameters were determined using a noncompartmental method (WinNonlin version 5.2.1; Pharsight Corporation).
Pharmacodynamics
PRP was obtained from patients pre-dose, and at 1, 3, 8, and 24 hours after dose on days 1 and 15 of cycle 1 for analysis of phospho-AKT (Ser 473 ) using an electrochemiluminescense assay (Luminex xMAP; Luminex Corp.). Wherever feasible, patients underwent tumor biopsies pretreatment and 1 to 4 hours after dose on day 15; samples were fixed, sectioned, and stained with hematoxylin and eosin, and for phospho-S6 using anti-phospho-S6 (Ser 235/236 ; Cell Signaling Technology Inc.), or anti-phospho-AKT (Serine 473) clone D9E (Cell Signaling Technology). Plasma was obtained pre-dose and at 1 hour after dose on cycle 1 day 1 for analysis of glucose and insulin levels at dose levels !100 mg. Whole-body 18 F-FDG-PET scans were performed at baseline, 1 to 4 hours after dose between day 22 and the end of cycle 1 as well as between day 50 and the end of cycle 2.
PI3K pathway alteration biomarkers
PIK3CA mutations were identified in circulating tumor plasma DNA (ctDNA) using a site-specific molecular characterization protocol (11) . Archival and fresh tumor samples were analyzed using the SEQUENOM OncoCarta Panel (Sequenom Inc.). PIK3CA amplification was assessed by fluorescence insitu hybridization (FISH) and PTEN status by immunohistochemistry (12) .
Results

Patient characteristics
Sixty patients with confirmed progressive cancer at study entry were enrolled, most of whom were heavily pretreated [median of 3 prior systemic therapies (range, 0-16); Table 1 ]. All patients were included in the safety analysis.
Treatment and dose escalation
Sixty patients were treated in 14 dose schedules (Table 2) . Dose escalation on the 21/28 schedule proceeded through 11 dose levels from 15 mg. At 450 mg, 2 of 3 patients experienced DLTs. The dose level of 330 mg was then evaluated with 1 DLT observed in 7 patients treated at this dose level on a 21/28 schedule. Subsequently, the dose levels of 330, 340, and 400 mg on the 28/28 schedule were assessed.
DLTs and MTD
The MTD was exceeded at 450 mg once-daily (21/28 schedule) with a DLT of grade 3 rash in 2 patients. This was a maculopapular rash covering 70% to 80% of the body surface area that presented approximately 2 weeks after commencement of daily pictilisib dosing and resolved spontaneously 2 weeks after treatment discontinuation. At 330 mg once-daily (21/28 schedule), the grade 3 maculopapular rash observed in 1 of 7 patients had a similar temporal pattern of onset and resolution; this was also declared as a DLT. On the 28/28 schedule, no DLT was observed.
Safety and tolerability
Pictilisib was well tolerated up to 330 mg (21/28 schedule); most AEs were mild to moderate in severity with no treatmentrelated deaths (Table 2) . At the assessed dose levels, there did not appear to be a significant difference in the toxicity profile between the 21/28 and 28/28 schedules. Treatment-related AEs that occurred in !10% of patients included: nausea, diarrhea, vomiting, fatigue, dysgeusia, decreased appetite, and rash. In addition to the two DLTs of grade 3 rash at the 450-mg dose level, the third patient at this dose level experienced grade 2 rash; nonetheless, this patient received 8 months of pictilisib with concomitant use of oral antihistamines and skin emollients. Of 10 patients treated with 330 mg once-daily (28/28 schedule), grade 1 or 2 rash was observed in 2 patients, and grade 3 rash (occurring after the DLTdefining window) in 2 patients; these similarly resolved with the introduction of drug holidays and supportive medications including emollients and corticosteroids.
Other clinically relevant drug-related AEs !grade 3 were grade 4 hyperglycemia (n ¼ 1; 130 mg) and grade 3 pneumonitis (n ¼ 1; 340 mg). The grade 4 hyperglycemia was transient, unaccompanied by clinically significant symptoms, signs or acidosis, and occurred in a patient with cholangiocarcinoma and previous pancreatico-duodenectomy who started low-dose prednisolone 2 days before the event. Grade 3 pneumonitis was observed at the end of cycle 1 in a patient with breast cancer previously treated with chest radiotherapy who developed grade 1 dyspnea, reduced DL CO and a ground glass appearance on HRCT; these resolved following 2 weeks of drug interruption and concomitant use of prednisolone. When pictilisib was reintroduced at 240 mg, the dyspnea and HRCT changes recurred; these subsequently resolved following permanent discontinuation of pictilisib due to disease progression.
Pharmacokinetics
Pharmacokinetic parameters of pictilisib were estimated for all dose cohorts and are summarized in Table 3 and Supplementary  Table S1 . Under fasting conditions, pictilisib was rapidly absorbed after oral administration [median T max of 2 hours (range, 0.5-8)]; this was independent of dose and was unchanged after multiple doses. Terminal plasma elimination half-life (T 1/2 ) on day 1 ranged between 13.1 and 24.1 hours. Dose-proportional increases in exposure (C max and AUC 0-24 ) was observed across the dose levels studied (Fig. 1) . Similar pharmacokinetic characteristics were seen on day 15. The accumulation index (AUC Day15 / AUC Day1 ) ranged from 1.2 to 2.2, suggesting modest accumulation following multiple doses.
Pharmacodynamics
We observed a dose-and concentration-dependent decrease in phospho-AKT in PRP on days 1 and 15 (Fig. 2) . Inhibition up to 90% of phospho-AKT level in PRP was demonstrated 1 Any AE  2  1  2  2  3  3  1  1  2  3  2  7  2  3  2  10 2  6  1  9  46  Gastrointestinal  Nausea  1  0  0  2  1  3  0  0  0  1  0  4  0  2  0  9  0  4  1  0 Including preferred terms of rash, rash maculo-papular, rash macular, rash pruritic, rash erythematous, and rash papular. b Including preferred terms of stomatitis, mucosal inflammation, mouth ulceration. to 3 hours after dose at the recommended phase II dose (RP2D); this effect was sustained (50% of baseline) at 24 hours after dose. Reductions in S6 and AKT phosphorylation in tumor biopsies were greatest at the highest exposure level of pictilisib (AUC >20 mmol/LÁh on day 15), with all 3 patients in this cohort showing !75% decrease in S6 phosphorylation and 2 patients also exhibiting a 100% decrease in AKT phosphorylation (Fig. 3) . Following pictilisib treatment at 330 mg on cycle 1 day 1, there was a statistically significant increase in plasma insulin and glucose levels at 1 hour from baseline with mean fold change (i.e., ratio of post-over pretreatment level) in plasma insulin and glucose levels of 3.58 [95% confidence interval (CI), 2.33-5.49] and 1.18 (95% CI, 1.10-1.26), respectively ( Supplementary Fig. S1 ). 18 F-FDG-PET imaging showed a reduction from baseline of 18 F-FDG-tracer uptake at dose levels !45 mg with an overall median change in maximum standardized uptake value (SUV max ) of À13% (range, À47 to 22; Supplementary Fig.  S2 ). Seven of 32 evaluable patients (22%) achieved a metabolic partial response by EORTC-PET criteria (>25% reduction in mean SUV max without new lesions) on 18 F-FDG-PET (10).
Antitumor activity
One patient with BRAF V600E-mutated metastatic melanoma, but no detected PI3K pathway deregulation, achieved a confirmed RECIST-partial response; she received pictilisib at 330 mg oncedaily (21/28 schedule) for 9.5 months. She had previously been treated sequentially with paclitaxel and dacarbazine, but had not received a BRAF or MEK inhibitor. A heavily pretreated, platinumrefractory advanced epithelial ovarian cancer patient with PIK3CA amplification (with high polysomy and >60% of tumor cells harboring four copies of PIK3CA) and loss of PTEN achieved radiologic stable disease for 4 months with GCIG-CA125 partial response (Supplementary Fig. S3 ; ref. 13 ) associated with 36% reduction in SUV max on 18 F-FDG-PET and 56% reduction in tumor phospho-S6 expression. A patient with cKIT exon 9 mutant gastrointestinal stromal tumor but no evidence of PI3K pathway deregulation achieved stable disease for 7.5 months on pictilisib 450 mg once-daily, and this was associated with pharmacodynamic changes of 47% reduction in SUV max on 18 F-FDG-PET and 75% reduction in tumor phospho-S6 expression.
Of 60 patients, 12 (20%) remained on study for >3 months and 2 (3%) for >6 months. Supplementary Table S2 shows the 
Discussion
In this first-in-human dose-escalation phase I study, we confirm the feasibility of safely inhibiting class I PI3K in patients with solid tumors. Pictilisib was well tolerated at doses shown here to modulate PI3K signaling in normal and tumor tissues, and demonstrated dose-proportional pharmacokinetics. The most common drug-related toxicities included grade 1-2 nausea, fatigue, diarrhea, vomiting, dysgeusia, and reduced appetite. The RP2D of oral pictilisib was 330 mg continuous once-daily dosing. DLT was grade 3 maculopapular rash occurring in 2 of 3 patients treated at 450 mg/day and 1 of 7 patients at 330 mg/day. Our data indicate that the severity of the rash was not clearly related to higher exposures of pictilisib ( Supplementary Fig. S4 ) and resolved with discontinuation of pictilisib. The rash was maculopapular but not acneiform or blistering, did not show a predilection for sun-exposed areas, and was similar to the rash observed with other PI3K, AKT, and mTOR inhibitors, thereby pointing to a mechanism-based toxicity (14) (15) (16) . Although this toxicity could be a potential pharmacodynamic biomarker of pictilisib, its underlying pathophysiology remains unclear and warrants further evaluation.
Our study design incorporated the use of the "Pharmacological Audit Trail" guidelines using appropriate pharmacokinetic-pharmacodynamic biomarkers (17, 18) . The audit trail has been used by both academia (19) and industry (20) as a guideline to help answer critical "go/ no-go" decisions based on scientifically measurable and rigorous endpoints. This audit trail has utility in providing broad guidance for drug development, even though the same precise effects in preclinical models may not be exactly reproduced in patients, as demonstrated in this trial. The favorable preclinical PK properties of pictilisib were reproduced in this phase I trial (9) . Preclinical pharmacokinetic-pharmacodynamic modeling based on MDA-MB-361, a human breast cancer xenograft with HER2 amplification and PIK3CA 1633G>A mutation, predicted the minimal target plasma AUC to be 6 mmol/LÁh (3000 ngÁh/mL) to achieve !90% tumor growth inhibition; this target AUC was achieved in most patients treated at doses >80 mg following 1 week of consecutive dosing and support the view that pictilisib is associated with biologically meaningful activity at these dose levels and exposures, especially at the RP2D. On the basis of these preclinical data, we additionally postulated that !90% inhibition of AKT phosphorylation is needed to inhibit cancer cell proliferation (9, 21) . We demonstrate here a dose-response relationship between drug exposure and target modulation in normal tissue, with up to 90% decrease in AKT phosphorylation in PRP at up to 3 hours after dose at the RP2D. Although a direct correlation between pictilisib exposure and decrease in S6 and AKT phosphorylation in tumor is less clear, at the highest level of drug exposure [AUC >20 hÁ(mmol/L)] there was clear evidence of pharmacodynamic effect, with >75% decrease in S6 phosphorylation and 100% reduction in AKT phosphorylation in 2 of 3 patients. The lack of consistent target modulation in tumor at lower drug exposures contrasts with the consistent dose-response relationship in PRP and is possibly related to different assay conditions that likely favor greater inhibition in the latter, together with disparities in drug concentrations between normal and tumor tissues due to probable differences in tissue architecture and hemodynamics. Such differences highlight the complexity of accurately defining the pharmacokinetic-pharmacodynamic relationship of molecularly targeted drugs, along with additional important issues including extrapolation of preclinical models to predict effects in patients, interpatient variation due to host pharmacogenomic variation, intra-and interpatient tumor heterogeneity, and differences in analytic sensitivity/methodology in PRP versus tumor biopsies. All of these are likely to be important, highlighting the importance of evaluating different pharmacodynamic biomarkers to increase confidence in the overall pharmacologic effects of a drug within the audit trail framework, as we have done here.
To this end, at the RP2D of 330 mg, we demonstrate multimodal pharmacodynamic evidence of target modulation including the reduction of 18 F-FDG-PET tracer uptake, inhibition of phospho-AKT in PRP and phospho-S6 in tumor tissue as well as increase in plasma glucose and insulin levels. These pharmacodynamic changes were observed regardless of molecular genetic status and from dose levels !100 mg.
PI3K signaling regulates insulin sensitivity, and hyperglycemia has been predicted to be a hallmark toxicity of PI3K inhibition (6, 22, 23) . However, pictilisib-related hyperglycemia was limited to grade 1-2 elevations in this study with grade !3 hyperglycemia being observed in only 1 patient with an extrahepatic cholangiocarcinoma who had undergone a previous pancreatic resection and was commenced on a corticosteroid 2 days before the AE. We confirmed target and pathway modulation at the RP2D with observations of convincing pharmacodynamic changes in phospho-S6 and 18 FDG-PET in tumor, and phospho-AKT, glucose and insulin in plasma. Nonetheless, it is possible that homeostatic mechanisms via negative feedback loops may cause drug resistance and account for the lack of more significant hyperglycemia.
The toxicity profile of pictilisib is in contrast to BKM120 (another pan-class I PI3K inhibitor) where rash, hyperglycemia, and mood alterations were the observed DLTs (15) . Apart from rash, the latter two were not significant toxicities of pictilisib. One would not have expected such differences if these DLTs are mechanism-based toxicities, especially when the observed in vitro potency of pictilisib is higher than that of BKM120 (24) . Pictilisib has a lower central nervous system (CNS) penetration than Change from baseline (%) pAKT pathology score pS6 H-score Figure 3 . Pharmacodynamic analysis in tumor biopsies. A, phospho-S6 (pS6) and phospho-AKT (pAKT) levels in baseline and on-treatment paired tumor biopsies grouped according to AUC0-24 [hÁ (mmol/L)] on day 15. pS6 staining levels were measured using a standard H-Score method, and pAKT staining levels were measured using a validated, qualitative scoring method (represented on y-axis). Pre-and ontreatment samples from the same patient were stained in the same experiment and examined blind. Arrows indicate patient 50036. B, immunohistochemistry images of pS6 and pAKT from patient 50036. C, percentage change from baseline of pS6 and pAKT levels. Tumor biopsies for three patients were not evaluable for phospho-AKT and are indicated with an "x." All patients received doses of >60 mg of pictilisib with the exception of patient 50008 who received 45 mg.
BKM120 while the targeted disruption of insulin signaling in the brain has been shown to lead to a diabetes mellitus phenotype (15, (25) (26) (27) (28) . It is likely that the marked hyperglycemia observed with BKM120 is due to the synergistic inhibition of PI3K signaling in peripheral tissues (e.g., muscle and adipose tissues) with noncanonical insulin-targeted tissues (including the brain), and the lack of CNS penetration may have enhanced the clinical therapeutic index of pictilisib relative to BKM120. The other pan-class I PI3K inhibitors that have undergone phase I clinical evaluation include SAR245408 and the irreversible wortmanin derivative PX-866 (29, 30) . Both drugs were associated with minimal hyperglycemia but differences were observed in the frequency of rash, which occurred in 26% of patients treated with SAR245048 (all grades) and in none of the patients treated with PX-866. The importance of the therapeutic window of the pan-class I inhibitors with regards to their pharmacodynamic effect is critical, and in this respect our hypothesis that !90% inhibition of AKT phosphorylation is needed to inhibit cancer cell proliferation reveals potentially important differences between pictilisb and the other drugs in this class, with SAR245048 reporting a 40% to 80% reduction in tumor AKT phosphorylation, in comparison to pictilisib achieving 100% AKT inhibition in two patients at the MTD.
There is currently no validated predictive biomarker for PI3K pathway inhibitors. Somatic mutational sequencing and assessment of PTEN expression status were therefore undertaken. Our results highlight ongoing difficulties in the attempt to identify predictive biomarkers for pan-class I PI3K inhibitors, with no clear relationship between PI3K mutation/amplification or PTEN expression status and response to pictilisib (3) . In this trial, PI3K pathway alterations were identified in 9 of 60 patients (15%), comprising 3 PTEN negative; 1 PTEN negative and PIK3CA amplification by FISH; and 5 PIK3CA mutations. Of these, none achieved a RECIST-based response and only 1 achieved a response by GCIG-CA125 criteria. This suggests the prediction of sensitivity may require more complex biomarker signatures rather than single mutational events (3, 21) . In addition, an association between 18 F-FDG-PET changes and RECIST response was not detected, in keeping with results from an earlier study of mTOR inhibitors (31) .
We note the modest response rates in this trial and therefore, while we postulate that approximately 90% inhibition of AKT phosphorylation for several hours is needed to inhibit cancer cell proliferation based on our preclinical tumor phosphorylation data (9), the exact duration and magnitude to which the pathway should be inhibited remains unclear and more work is required to relate the extent of downstream phosphoprotein biomarker modulation to efficacy in patients. We also believe that important distinctions should be made between the utility of reduction in AKT phosphorylation as a pharmacodynamic and predictive biomarker of response. The best RECIST-responder in this study bore a BRAF V600E-mutant melanoma with no demonstrable PI3K mutation; she achieved a radiologic partial response by RECIST and remained on pictilisib for 9.5 months (she was not previously treated with a BRAF inhibitor and this was not therefore a withdrawal response). Responses to PI3K pathway inhibitors have been reported in BRAF-mutated cancer cell lines, including those without any known PI3K pathway aberration (32) . Although these cancer cell lines are primarily dependent on RAS-RAF-MEK-ERK signaling for their proliferation, they are likely to have a degree of codependence on the PI3K-AKT pathway for their proliferation and survival, possibly explaining the response to pictilisib in this patient. In addition, there may be other activating effects in the PI3K pathway that we have been unable to assess that predispose to sensitivity including potential immunomodulatory effects given that T-cell receptor signaling involves the PI3K pathway (33) .
An increasing understanding of potential resistance mechanisms (21) and promising preclinical data from combinatorial use of pictilisib (34) (35) (36) has led to clinical trials of pictilisib in combination with drugs including erlotinib, fulvestrant, trastuzumab emtansine (Kadcyla), GDC-0973 (a MEK inhibitor), paclitaxel, and chemotherapy regimens comprising paclitaxel/bevacizumab, carboplatin/paclitaxel/bevacizumab, and cisplatin/ pemetrexed. Results from these ongoing studies are awaited.
In summary, pictilisib was safely tolerated at doses up to the RP2D which is 330 mg once-daily administered continuously. Displaying favorable pharmacokinetic properties, the plasma exposure levels achieved with !80 mg once-daily dosing were consistent with those associated with effective target modulation and antitumor activity predicted by preclinical in vivo pharmacokinetic-pharmacodynamic modeling. Analysis of pharmacodynamic biomarkers in peripheral blood and tumor tissue crucially provided evidence of significant PI3K pathway modulation at the RP2D. There is also evidence of clinical antitumor activity. Overall, these data provide strong support for the continued clinical evaluation of pictilisib. 
